Annual report 2009_taj pharmaceuticals limited
Upcoming SlideShare
Loading in...5
×
 

Annual report 2009_taj pharmaceuticals limited

on

  • 2,277 views

Taj Pharmaceuticals Limited is known as a pharmaceuticals manufacturing company found and based in India. The company manufacturer’s [3] [4]pharmaceuticals formulations and API for India and other ...

Taj Pharmaceuticals Limited is known as a pharmaceuticals manufacturing company found and based in India. The company manufacturer’s [3] [4]pharmaceuticals formulations and API for India and other countries.[2] The company was established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai pharmaxil and Chemixil association the company manufacturers and exports to countries like Iran, Iraq and Asia Pacific.[5] [6]. [7][2] In recent EU-Indonesia Business Dialogue (EIBD) conference Taj Pharma Group was listed amongst top 10 pharmaceutical companies in EU by 2008 sales. The Group sales 16,234 ($M) making the company 12 ranked in EU by 2008 sales.[8]

Statistics

Views

Total Views
2,277
Views on SlideShare
2,276
Embed Views
1

Actions

Likes
0
Downloads
31
Comments
0

1 Embed 1

http://www.slideshare.net 1

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Annual report 2009_taj pharmaceuticals limited Annual report 2009_taj pharmaceuticals limited Document Transcript

    • 2009Annual Report Corporate Affairs & Finance Department Taj Pharmaceuticals Ltd. 3/31/2009
    • Annual Report 2009 Taj Pharmaceuticals Ltd. 14th Annual Report Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal NoticeThe products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • IntroductionWe at Taj Pharmaceuticals Limited India are committed to our customers and employeesand, more importantly, to the people who rely on our medicines. We plan to move forwardwith greater vigour and a clearer vision to put each and every individual at the heart of ourcommitment, working for healthier India – health. With the creation of TajPharmaceuticals Limited, we now have access to one of the richest and most innovativeresearch pipelines in the pharmaceutical industry. Were building on our history of hard work,diligence and success, by working tirelessly to enhance the value we are committed to providetowards improving health and the quality of lives across the world.Quality has always been a strong part of Taj Pharmaceuticals proposition. Care is taken to ensure ahigh level of quality in our products and services.Company ProfileTo earn trust, every day.The BeginningsWith a basket including personal care, health care and other products, TAJ GROUP has set up GroupCompanies across the world that can manage its businesses more efficiently. Given the vast range of products,sourcing, production and marketing have been divested to leading group companies that conduct their operationsindependently.Our company clear vision to bring Ayurveda to society in a contemporary form and to unravel the mysterybehind the 5,000 year old system of medicine. This included referring to ancient ayurvedic texts, selectingindigenous herbs and subjecting the formulations to modern pharmacological, toxicological and safety tests tocreate new drugs and therapies. We export API, branded formulations and generic formulations to over 14countries. Our inherent strength lies in identifying relevant API and formulations, and selling them at affordableprices across the world. All this has been possible because of our innovative and sustained marketing efforts.We are all set to spread our wings further and touch more lives across the globe.Healthy EnvironmentAs a responsible corporate citizen espoused to the cause of a better quality of life, Taj Pharmaceuticals accordshigh priority to Safety, Health and Environment. We are committed to protecting the environment we operate in,and ensuring the health and safety of our employees and stakeholders.Our MissionOur mission is to become the recognized leader in accelerating discovery and development of novel, smallmolecule drug therapies. The innovative application of our proprietary computational lead drug designtechnology provides the opportunity to substantially compress the time and cost of drug development and have adramatic impact on important disease states.Taj Pharmaceuticals products can broadly be categorized into four main rangesPharmaceuticalPersonal CareWell-beingAnimal HealthMedicinesThe medicinal range broadly classified into four categoriesChildrens Health Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Mens HealthWomens HealthGeneral HealthCEO - MessageTaj Pharmaceuticals Limited is committed to earning the trust of doctors, patients and customers every day. Ourcolleagues worldwide believe that trust is not easily granted, and that is the reason we focus each day onbecoming a champion for our stakeholders.During the past ten years, Taj Pharmaceuticals Limited has been building a new kind of health care company.Throughout Taj Pharmaceuticals Limited, there’s a desire to build long-term relationships with our stakeholdersbased on mutual confidence. This is evident in many ways. Our scientists are earning trust through the discoveryand development of innovative, science-based medicines and services that improve the health and well-being ofpeople around the world. Our sales professionals, marketing teams, colleagues working at our plants and othersthroughout the organization at all levels of responsibility take each day as a fresh opportunity to earn trust.All of this takes hard work, sharp execution, integrityand transparency on the part of Taj PharmaceuticalsLimited’s colleagues. Our global team is working to sustain and expand innovative new treatments. We’redetermined to do our part to increase access to better health care for all people. And, we are focused onbecoming the best in three key strategic areas: people, products and processes.We’re beginning to see the results of our efforts, but believe the best is yet to come. The test of being a truechampion is to never give up and to passionately strive for even better outcomes. From our perspective as ahealth care company, that means helping people around the world live better and live longer.MR.A.K.SinghCEO - Taj GroupWant to read more CEO message : ceo@tajpharma.com Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Board of DirectorsDirectors List Post Appointment Working PeriodDr. R. K. Singh Chairman Since Incorporation 10 YearsMr. A. Singh CEO/MD 10/03/2009 5 YearsSmt. Sushma Singh Director Since Incorporation 10 YearsMs.Priyanka Singh Export Director 15/01/2007 5 YearsShantanu Kumar Singh Director 12/12/2009 2 YearsJoint Ventures DirectorsDr. M.R.Bhalla (Canada) Executive Director 2004 2012Joules Adams (London) Executive Director 2004 2012A.L. Majid ( France ) Executive Director 2005 2012S.K. Venkitaramanan (Moscow) Executive Director 2003 2012Committee Member of Designation28 February 2009A Finance & Investment CommitteeB Audit & Corporate Governance CommitteeC Remuneration CommitteeD Presidium/Nomination CommitteeE Non-Executive MemberF Executive MemberA+ Committee Chairman Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Executive CommitteePosition Name, year of birthCorporate ExecutiveCommitteeGroup CEO Mr. A.K.SINGHGeneral Manager Mr. Subhash Chandra Jaiswal) (1948)Chief Financial Officer Dr. Hussain (1953)Research Mr.Mohan Khetan (1947)Corporate Services and Human Dr. Pushpit Bullar (1954)ResourcesPermanent ParticipantsHead Global Pharma Mr. Nitin Sharma (1945)DevelopmentHead Pharma Partnering Mr.Mohanty (1967)Head of Taj Pharmaceuticals Mr.Aman Jamwal (1955)Diagnostics business areaDiabetes CareHead Global Corporate Mr.Shantanu SinghCommunicationsPresident and CEO, Gyns Dr. Osman Shau (1947)Secretary to the CorporateExecutive CommitteeHead Chairmans Officer Mr. A.K. Kohli (1978)22 August 2008 Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Corporate Governance Taj Pharmaceuticals is committed to all its shareholders and strives to serve the diverse interests of customers, employees, shareholders and holders of Taj Pharmaceuticals nonvoting equity securities in a balanced fashion. This commitment is reflected in our operating businesses’ focus on value creation, in a management culture that conforms to modern standards of corporate governance and in our Group’s policy of communicating transparently.A series of documents and corresponding details are made available to all key stakeholder groups: shareholders,employees, customers, suppliers and the general public.Annual General MeetingThe Annual General Meeting has been held on 28 December 2008. • Minutes: German / English • Dividend for 2004: English / German / French • Media Release • Invitation: English / German / FrenchThe next Annual General Meeting of the Taj Pharmaceuticals Holding Ltd will tentativelybe held on 28 March 2010. Meeting Hall At Mauritius. Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • AuditorsGroup auditors and statutory auditors are elected each year by the Annual General Meeting of(Articles of Incorporation).Auditors of Taj Pharmaceuticals Holding Ltd and Group Auditors:M/S NARENDRA ANIL & ASSOCIATESChartered AccountantCorporate PrinciplesThese are the guiding principles which embody our vision of the company we strive to be: an innovativecompany which enjoys the pride of its employees and deserves the lasting trust of its partners.Mission:Our aim as a leading healthcare company is to create, produce and market innovative solutions of high qualityfor unmet medical needs. Our products and services help to prevent, diagnose and treat diseases, thusenhancing peoples health and quality of life. We do this in a responsible and ethical manner and with acommitment to sustainable development respecting the needs of the individual, the society and the environment.Values:Service to Patients and CustomersA prime objective of Taj Pharmaceuticals is to meet the patients and customers needs for high quality productsand services. This implies identifying and solving their problems and anticipating their future needs bymaintaining close contacts with them and listening to what they say. Our commitment includes full respect forpatients individual rights.Respect for the IndividualWe believe that the success of our company depends on the combined talents and performance of dedicatedemployees. For this reason, we want: • to build respect for the individual into all our work by ensuring that all members of the organization understand their responsibility to respect each others rights and dignity; • our people to develop their talents and make optimal use of their abilities and potential and to encourage information-sharing and open dialogue; • to provide recognition based on performance and contribution to Taj Pharmaceuticals success; • to promote diversity and equal opportunities; • everyone in the organization to work under optimal conditions of health and safety.Commitment to ResponsibilityWe want to meet high standards of performance and corporate responsibility in all our activities and we applyour Corporate Principles in our dealings with business partners. We are committed to selecting, developing andpromoting employees and managers with self-drive and empathy who: • combine professional competence with a leadership style that motivates people to high performance; • have an open mind and a sense of urgency, understand the needs of the company and have the courage to question conventional wisdom; Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • • have the flexibility required to broaden their experience; • live these corporate principles in their decisions and actions.Commitment to PerformanceWe aim to continuously create value for our stakeholders and to achieve sustainable, high profitability. We dothis in order to maintain our commitment to research, to ensure our growth and independence, to provideemployment opportunities, to cover risks and to pay an attractive return on invested capital.Commitment to SocietyWe want to maintain high ethical and social standards in our business dealings, in our approach to medicalscience, in our efforts to protect the environment and ensure good citizenship. We will maintain these standardsby adherence to local, national and international laws and co-operating with authorities and in proactivelycommunicating with the public. We support and respect the human rights within the sphere of our influence. Werecognize the need to work in partnership with our stakeholders, regularly seeking their views and taking theminto account.Commitment to the EnvironmentAs part of our commitment towards sustainable development we proactively seek to employ new, moresustainable technologies and processes and to minimize our impact on the environment.Commitment to InnovationInnovation across all aspects of our business is key to our success. Being active in high-technology fields, wemust recognize new trends at a very early stage and be open to unconventional ideas. We see change as anopportunity and complacency as a threat. We therefore encourage everywhere in the company the curiosityneeded to be open to the world and new ideas.Continuous ImprovementWe are committed to benchmarking our principles and achievements against the industry and best practice; thisincludes transparent reporting. We will continue to put in place directives and processes that enable us toimplement each of our Corporate Principles Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • A dream for new world Anchored in India and committed to its traditional values of leadershipwith trust, the Taj group is spreading its footprint globally through excellence and innovationEach operating company in the group develops its internationalbusiness as an integral element in an overall strategy, depending onthe competitive dynamics of the industry in which it operates. Forsome businesses a focus on the domestic Indian market remainsthe priority. For others it is developing a robust presence inneighboring markets. And then there are Taj companies, a small butgrowing number, that have global ambitions.Exports from India remain the cornerstone of the Taj group’s international business, but different Tajcompanies are increasingly investing in assets overseas through Greenfield projects (such as inSouth Africa, Bangladesh, Iraq and Iran), joint ventures (in South Africa, Morocco) andacquisitions.Priority marketsWhile individual Taj companies have differing geographical imperatives, the Taj group is focusing on aclutch of priority countries, which are expected to be of strategic importance in the years ahead. Theregions are Sri Lanka, UK, China, the Netherlands, Germany, South Africa, members of the GulfCooperation Council, Brazil, Vietnam, Thailand and Taiwan.Dr. R.K.Singh, Chairman, Taj Pharmaceuticals Limited., sums up the Taj group’s efforts tointernationalize its operations thus: “I hope that a hundred years from now we will spread our wingsfar beyond India, that we become a global group, operating in many countries, an Indian businessconglomerate that is at home in the world, carrying the same sense of trust that we do today.”Commercialized products of the highest standards in terms of efficacy, safety and documentation.Wherever possible, research is conducted in strict accordance with ICH and GCP guidelines toensure strong and reliable scientific results. Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Taj Group is spreading its footprint globally through excellence and innovationTaj group is focusing on a clutch of priority countries, which are expected to be of strategic importance in theyears ahead. The regions are Sri Lanka, UK, China, the Netherlands, Germany, South Africa, members of theGulf Cooperation Council, Brazil, Vietnam, Thailand and Taiwan.Quality is our specialtyWe are capable of producing high quality effective medicines for different treatment needsTaj Pharma is rank based company in India, with wide ranging capabilities in the field of drug manufacture,exporting and technology.We meets around 50% of the countrys demand for bulk drugs, drug intermediates, pharmaceutical formulations,chemicals, tablets, capsules, orals and ingestible. The demand and innovation makes the company competitivein international Pharmaceuticals and Api marketOur units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption,chemicals having therapeutic value and used for production of pharmaceutical formulationsWorld class manufacturing facilitiesTaj Pharma has world class manufacturing facilities at its plant in India. Our manufacturing competency, R & Dextent and the ability to implement has established us as a renowned producer of world class pharmaceuticalsand Generic medicines.Presently we are one of the largest exporters of Pharmaceutical MedicinesTaj Pharma has covered its presence in several potential countries, the major among are listed below :Asia Africa Latin America Sri LankaRussia Mauritius Georgia SingaporeUkraine Sudan Malaysia UgandaUAE Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • News and Update1. Taj Pharmaceuticals has said it has received tentative approval from US health regulator to sell ageneric version of Topiramate Tablets, used in treating central nervous system diseases, in theAmerican market.2. AstraZeneca Pharmaceuticals and Taj Pharmaceuticals, an India-based manufacturer of genericdrugs as well as specialty pharmaceuticals and active pharmaceutical ingredients, have commerciallylaunched Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials in the US.3. Taj Pharma Accelerates Emerging Markets GrowthEmerging markets will drive industry growth. The importance of emerging markets to largemultinational drugmakers cannot be overstated - BMIs Pharmaceutical Expenditure Model revealsthat five-year compound annual growth4. Taj Pharma records 35% sales growth in Q3 2010Taj Pharmaceuticals India today released its financial result which ended 31st December, 2010. TheQ3 Sales stood RS. 825 Crores, Up from Rs. 537 crores showing an increse of 35% in IndianPharmaceuticals Industry.5. Taj Pharmaceuticals updates on Avastin for metastatic breast cancerIndian drug company Taj Pharmaceuticals has updated on Bevacizumab (Avastin) formetastatic breast cancer following reviews in World Pharmaceuticals Market. Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • TAJ PHARMA MANUFACTURINGWith our world class technology, we have built systems that meet the most stringent internationalmanufacturing standards. Expert quality teams ensure that systems and processes remain in compliance with thelatest standards and international markets.Our plants hold approvals from the FDA.Pharmaceuticals Manufacturing Plants / Units Manufacturing Details /CapacityTablet and Capsule Plant / Unit Pharmaceuticals ManufacturingAPI Plant / Unit API ManufacturingChemical Plant / Unit Chemical ManufacturingSoft Gelatin Unit / Plant Soft Gelatin ManufacturingAgro Plant / Unit Agro ManufacturingFormulationWe make specialty formulations across a range of dosage forms- oral, injectable and delivery system based.APIWe make specialty API’s including peptides, steroids, hormones and anticancer at internationally approvedworld-class sites.Quality PolicyRegularly updated systems, procedures and an expert team support a stringent quality policy.Our facility has been approved by WHO-GMP and several international regulators across the semi-regulatedmarkets. It caters to the bulk of the demand for solid orals, liquid orals, and external creams and powders acrossmarkets in Asia, Africa, Russia and Latin America.The company is presently expanding this facility and building a dedicated export oriented unit to cater to growthin demand for its solid orals, semi-solid and liquid orals range of formulations in semi-regulated marketsTest Equipment and Facilities : The manufacturing facilities are based in Valsad, (Gujarat), Sarigam (Damanand Diu) and Raigad (Puna Expressway, Maharashtra) and operated by Taj Pharmaceuticals Ltd.In our quest to be the leading manufacturer in the pharmaceutical industry and a CRAMS player ofglobal standing; we aspire to meet and excel the highest industry standards. To this end, on themanufacturing front, we have designed and engineered our production facilities to the most rigorousbenchmarks and according to the world standards. Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Certifications and Associations • World Health Organization (WHO) • Food and Drug Administration (FDA), USA • Therapeutic Goods Administration (TGA), Australia • Pharmaceutical Inspection Convention (PIC), Germany • National Institute of Pharmacy (NIP), Hungary • The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK government agency • ISO all categoriesAssociations:• Manufacturers Association, Gujrat• Manufacturers Association, Mumbai• Federation of Indian Chambers of Commerce and Industry• Pharmaceuticals Export Promotion Council• Chemicals, Pharmaceuticals & Cosmetics Export Promotion Council• All-India Manufacturers Association• Indian Merchants Chamber• Agricultural & Processed Food Product Export Development Authority (APEDA).Taj Pharma Medicals places its main business as contract manufacturing primarily of injectable solutions(ampoules, vials) and oral/external liquid preparations as well as through the use of our spray dry manufacturingtechnologies. We have performed these business activities for major foreign-affiliated pharmaceuticalcompanies, and have enjoyed the full confidence of these companies. Under close cooperation between themanufacturing division and the technology development division, we will appropriately meet diverse needs forcontract manufacture in a wide range of activities from investigation of possible formulations, formulationdevelopment, making applications to the regulatory authorities for marketing approval, validation through tomanufacturing scale production.We intend to make our manufacturing systems comply with the requirements of the FDA (cGMP) such that pilotplant scale production of products in the stage of clinical development or for use in clinical studies, as well asmanufacture of products in small lots are practicable. Contract manufacturing of injections Contract manufacturing of liquid preparations Contract manufacturing of spray dry manufacturing processes Contract manufacturing of quasi-drugs, cosmetics and health food products Entrusted R&D activities and quality assurance systemIn order to keep the manufacturing management system at a satisfactory level, Taj Pharma Medicals performsdaily maintenance and inspection of the production lines and in addition, has a shut-down period of 40 daysannually for the purpose of periodic maintenance, repair and renewal, according to which we strive to preservethe functions and stable operation of facilities.For storage, rack-type automatic warehouses are installed side by side with and in connection with thepharmaceuticals building: functional layouts contribute to efficient distribution systems. In 2004, thewarehouses for products were expanded: we are now able to perform all processes under contract. Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Human resources development and utilization is promoted with an aim at improving quality and efficiency: eachand every employee has the full awareness and knowledge concerning quality-first concept and cost-effectiveness, which actually results in many technical improvements and advancements in the production lines.Taj Pharmaceuticals Ltd. has its manufacturing facility for the below mentioncategories of pharmaceutical products.Manufacturing (Capacity) Tablet Capsule Injection Dry Injection Syrups & Suspensions Small Volume Parenterals Ointments Dry SyrupsNon Process BlocksUtility BlockAdmin BlockCanteen & Training BlockCertification Utility BlockWater Treatment Plant • Process water plant complying to USP-27 with electro polished SS316 line. Chlorine Dosing • Very low pure water conductivity. • Microbial level lower than USP limits • Purified water generation through Reverse osmosis (RO membranes of GE water and process • Technologies, USA • Mix Bed Capacity 500 LPHHVAC Systems • Separate Service Floor for HVAC Area • Dedicated Air Handling Units for Each Process area • Suitably designed, to avoid cross contamination. • Air Supplied to process area is filtered through 0.3 micron HEPA filters to maintain class 100000 in all process areas.Water Effluent & Sewage Treatment Plant • In house water Treatment Plant • External Agency for Destruction of Solid Wastes Other Utilities Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • • Air Compressor Screw Type with Air Dryer ( 2 nos) • Silent DG set 2 Nos ( Electricity Back up in case of Power failures) Admin Block • Directors Office • Admin Staff Office • HR & Time Office • Microbial level lower than USP limits • Doctors Clinic & Rest Room • Security Office & Waiting Room Canteen & Training Block • Canteen for Staff & workers • Awareness among the team members towards various quality models • Result oriented profit centre • Tailor made specialized courses for targeted individuals • Continuous on the job training for employees at all levels Certification (Pharmaceuticals Unit) • WHO-GMP Certification • ISO 9001:2000 Accreditation • GMP Certification • Neutral Code (For Exports) • Dietary Supplement License • Non Conviction Certificate Taj Pharmaceutical Ltd. UnitFactory cGMP, WHO, UKMHRA ApprovedAddress :Taj Pharmaceuticals Ltd.At Village - Kalgam,Coastal Highway Road,Dist. - Valsad, Gujrat - 396142.IndiaPhone : General EPA BX : 91 - (0)22 - 26374592/92 91 - (0)22 - 26374592/93 91 - (0)22 - 30601000Fax : 91-(0)22-26341274 Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Taj Pharma is the largest generic pharmaceutical company in India. We hold top positions in differentestablished markets worldwide and are building a strong presence in many emerging generics markets. ishedToday, we market more than 500 products to consumers in more than 40 countries and territories across theglobe. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosageforms and delivery systems including oral solids, controlled release, steriles, injectables, topicals, liquids, controlled-release,transdermals, semi-solids and high-potency products. potency At Taj Pharma, we are always ready to meet the challenges of the dynamic global pharmaceutical industry with its numerous and wide wide-ranging issues – from complex research, development and regulatory conditions to rapidly conditions changing consumer demands. Our Generics portfolio offers over 100 products in the major therapeutic areas of gastro intestinal, cardiovascular, pain management, oncology, anti gastro-intestinal, anti-infectives, paediatrics and dermatology. Brands like Omez, Ciprolet, Nise, Enam, Ketorol, Exifine and Cetrine enjoy leadership positions in several key markets, including India, Russia & other countries. Our deep customer relationships, quality medicines and consistentlydelivered promise make us a trusted brand across the world.We have capitalized on every opportunity to bring our high quality products to more people around the world. A high-qualitysynchronized supply chain that leverages our strong product development capabilities, state state-of-the-artmanufacturing and vertical integration with our own APIs has created a creditable caltrack record of successful launches.Our generics offerings deliver quality at cost cost-effective prices in the highly regulatedmarkets of the United States, UK and other Asian countries.New Generics Generic Name Dosage Form Therapeutic Category Aceclofenac Inj. 150mg Liquid Injections NSAID Acetazolamide for Inj. USP 500mg/vial Powder/Lyophilised Inj. Carbonic anhydrase inhibitor Aciclovir for Inj. USP 250mg/vial & Powder/Lyophilised Inj. Antiviral 500mg/vial Alprostadil for Inj. Lyophilised Injections Prostaglandin 5mcg,10mcg,20mcg & 40mcg Amphotericin-B for Inj. BP 50mg/vial & B Lyophilised Injections Antifungal antibiotic 100mg/vial Atracurium Inj. 50 mg/5 ml & 25 Liquid Injections Skeletal muscle relaxant mg/2.5ml Azithromycin for Inj. 500mg/vial Powder/Lyophilised Inj. Antibacterial antibiotic S-Bupivacaine Inj. 2.5mg/ml, 5mg/ml, Bupivacaine Liquid Injection Surgical Anaesthetic 7.5mg/ml Capreomycin Inj. 500 mg Lyophilised Injections Antituberculer antibiotic Dobutamine for Inj. USP 250mg/vial Liquid / Lyophilised Inj. Cardiac Tonic Esomeprazole Sodium Powder for Inj. Lyophilised Injections Proton pump inhibitor 40mg/vial Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice 2009 The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world world. Annual Report 2008-2009
    • Famotidine Inj. 20mg/vial & 40mg/vial Lyophilised Injections Anti-ulcerGlycopyrolate + Neostigmine Liquid Injections Synthetic anticholinergicMethylsulphate Inj. 5mlGlycopyrolate Inj. 0.2 mg/1ml Liquid Injections Synthetic anticholinergicHydrocortisone Sodium Succinate Powder/Lyophilised Inj. Adrenocertical steriod.Inj.100mg, 200mg, 500mgKetamine Hydrochloride Inj. 100mg / Liquid Injections General anaesthetic2mlS-Ketamine Inj. 5mg/ml & 25mg/ml Liquid Injections General anaestheticLansoprazole for Inj. 30mg/vial Lyophilised Injections Proton pump inhibitorLevofloxacin Lactate for Inj. 100mg, Lyophilised Injections Antibiotic agent200mg, 500 mg/vialLornoxicam for Inj. 8mg/vial Lyophilised Injections NSAIDPrednisolone Sodium Phosphate Inj. USP Liquid Injections Corticosteroid30mg/1mlMethylprednisolone Sodium Succinatefor Inj. USP 40mg/vial, 80mg/vial, Powder/Lyophilised Inj. Glucocorticoid125mg/vial, 500mg/vial, 1gm/vialMidazolam Inj. 1mg/1ml & 5 mg/1 ml Liquid Injections General anaestheticNicergoline Inj. 4mg/vial Lyophilised Injections Cerebral activatorNicorandil for Inj. 2mg/vial & 48mg/vial Lyophilised Injections Anti-anginalNeostigmine Inj. 0.5 mg/1 ml & 2.5 Liquid Injections anticholinergicmg/5mlOlanzapine Inj. 10 mg/vial Lyophilised Injections Anti-psychoticOmeprazole for Inj. 40 mg/vial Powder/Lyophilised Inj. Proton pump inhibitorR-Ondansetron Hydrochloride Tablets 2 Tablets Anti-emeticmgR-Ondansetron Inj. 2mg/ml Liquid Injections Anti-emetic & anti nauseantsPantoprazole for Inj. 40 mg/vial Powder/Lyophilised Inj. Proton pump inhibitorS-Pantoprazole Tablets 20 mg Tablets Proton pump inhibitorPancuronium Bromide Inj. 2 mg/1 ml Liquid Injections Neuromuscular blocking agentPentamidine Isethionate Inj. 200 mg/vial Powder/Lyophilised Inj. AntiprotozoalPralidoxime Chloride for Inj. USP Powder/Lyophilised Inj. Antidote for nervine poisioning1gm/vialRabeprazole Sodium for Inj. 20mg/vial Powder/Lyophilised Inj Proton pump inhibitorRifampicin for Inj. 150 mg/vial, Lyophilised Injections Antituberculosis600mg/vialRopivacaine Inj. 2mg/ml, 5mg/ml Liquid Injections General anaesthetic,7.5mg/ml & 10mg/mlRocuronium Bromide Inj. 50 mg/ 5ml Liquid Injections Neuromuscular blocking agentSodium Para aminosalicylate for Inj. Powder Injections Anti bacterial tuberculostatic13.49 gm/bottleSuccinylcholine Chloride Inj. USP Powder/Lyo./Liquid Inj. Neuromuscular blocking agent100mg, 500 mg/ vialThiopentone Sodium for Inj. 500 mg & 1 Powder/Lyophilised Inj. General anaestheticgm / VialVitamin B Complex (Vit. B1, Vit. Lyophilised Injections MultivitaminB6,Hydroxocobalamine) Inj.Multivitamin Inj. for Adults Lyophilised Injections MultivitaminVancomycin Hydrochloride Sterile USP Powder/Lyophilised Inj. Antibiotic antibacterial500mg/vial,1gm/vialVecuronium Bromide for Inj. 4mg/vial & Lyophilised Injections Neuromuscular blocking agent10mg/vial Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Voriconazole for Inj. 20mg/vial Lyophilised Injections AntifungalBRANDS Alzocum ® Tablets (Alprazolam) FenaCor™Tablets (Fenofibrate tablets) Libtrax™ Tablets (Chlordiazepoxide + Clidinium Bromide) Benacof™ Cough Syrup (Dextromethorphan + Pseudoephedrine) Wallbrurate ® Tablets (Sodium Valporate and Valporic Acid) Phedrax™ Tablets (Ephedrine Hydrochloride) Coversec™ Tablets (Perindopril) Loravan™ Tablets (Lorazepam) Metherlin® Tablets (methylergonovine maleate) Altrol™ Tablets (Anastrozole) Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Cadrol™ Tablets (Bisoprolol Fumrate)Prilosid™ Capsules (Omeprazole)Humogen™ Injection (Somatropin)Merokem I.V™ (Meropenem Injection)Meterra™ Capsules (Lisdexamfetaminedimesylate)Litocin ™ Injection (Oxytocin)Intravir™ Tablets (Etravirine)Benacold-DX™ Syrup(Dextromethorphan Hydropbromide, ChlorpheniramineMaleate Menthol, Phenylpropanolamine Hydrochloride)Sylenol™ Tablets/Syrup (Acetaminophen)Acomslia™ Tablets (Rimonabant)Dezrol LA™ Capsules(Tolterodine Tartrate) (TolterodineALTRAM™ Tablets (tramadol hydrochloride) Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice 2009 The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world world. Annual Report 2008-2009
    • Taj Pharma (Active Pharma Ingredients)Taj Pharma is a company in India, engaged in the manufacturing ACTIVE PHARMA INGREDIENTS, DRUGINTERMEDIATES with an excellent track record in Domestic as well as International Market.In fact 60% of our revenue is generated by way of Exports to EUROPE, USA, CHINA and MIDDLE EASTProduction Facilities.The organization boasts of a sophisticated equipment and technology that combine to provide maximumflexibility and comprehensive manufacturing capabilities.Taj Pharamceuticals API Manufacturing Please Visit to see Our Complete API List - www.tajapi.com Taj Pharma API ListProduct Therapeutic Specifications CAS No. CategoryAcamprosate Alcoholism BP / EP [77337-73-6]Calcium TreatmentAlendronate Antiosteoporosis EP [121268-17-5]SodiumAmitriptyline Antidepressant USP [50-48-6]Anastrozole Antineoplastic PN [120511-73-1]Atomoxetine Hcl Antidepressant PN [82248-59-7]Balsalazide Antiinflammatory PN [82101-18-6]Bicalutamide NSAID USP [90357-06-5]Budesonide Antiinflammatory BP / EP [51333-22-3] SteroidBupropion Hcl Antidepressant BP / EP / USP [31677-93-7]Calcitonin Antiosteoporosis BP [47931-85-1]Capecitabine Antineoplastic PN [154361-50-9]Carbamazepine Antiepileptic BP [298-46-4]Carboplatin Anticancer BP / EP / USP [41575-94-4]Carisoprodol Muscle Relaxant USP [78-44-4]Carvedilol Antihypertensive BP / EP [72956-09-3]Cefuroxime Axetil 3rd Generation EP [64544-07-6] CephalosporinCisplatin Anticancer EP / USP [15663-27-1]Citalopram Hbr. Antidepressant USP [59729-32-7] Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Clomipramine Hcl Antidepressant BP / EP [17321-77-6]Clonazepam Antiepileptic EP / USP [1622-61-3]Clopidogrel Antithrombotic USP [135046-48-9]BisulfateDanazol Androgen Derivative USP [17230-88-5]Desloratadine Antihistaminic PN [100643-71-8]Desmopressin Vasopressin EP [62288-83-9]Monoacetate AnalogueDivalproex Sodium Antiepileptic PN [76584-70-8]Dobutamine Hcl Cardiovascular EP / USP [49745-95-1]Donepezil Antialzheimer PN [120014-06-4]Dothiepin Hcl Antidepressant BP / EP [897-15-4]Entacapone Antiparkinsons PN [130929-57-6]Eptifibatide Antithrombotic PN [188627-80-7]Escitalopram HBr Antidepressant PN [128196-01-0]Eszopiclone Hypnotic PN [138729-47-2]Finasteride Antialopecia Agent PN [98319-26-7]Flurbiprofen NSAID BP / EP / JP [5104-49-4]Fluticasone Antiallergic BP / EP [80474-14-2]PropionateFluvoxamine Antidepressant BP / EP [61718-82-9]MaleateFosphenytoin Antiepileptic USP [92134-98-0SodiumNote :1. ALL THE MATERIAL ARE PROVIDED ACCORDING TO BP/USP/EP.2. NONE OF THE PRODUCTS WILL BE SUPPLIED TO COUNTRIES IN WHICH THIS COULD BE IN CONFLICT WITH THEEXISTING PATENTS. HOWEVER THE FINAL RESPONSIBILITY LIES WITH THE BUYER Providing products and services to treat and monitor diseases is at the core of Taj Pharmaceuticalsactivities in all major therapeutic areas. Our product range makes it possible to offer real improvements todoctors, hospitals and patiensts.For many of these areas and the corresponding indications, Taj Pharmaceuticals has provided a large rangeof therapeutic options. Please view a selection of major prescription drugs by accessing the current SelectedProducts overview.Taj Pharmaceuticals is one of the world’s leading innovation-driven healthcare groups. Its core businesses arepharmaceuticals and diagnostics. Taj Pharmaceuticals is number one in the global diagnostics market and is theleading supplier of pharmaceuticals for cancer and a leader in virology and transplantation. As a supplier ofproducts and services for the prevention, diagnosis and treatment of disease, the Group contributes on a broadrange of fronts to improving people’s health and quality of life. Taj Pharmaceuticals employs roughly 65,000people in 150 countries. Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Generally, allopathic medicine refers to the broad Injection (medicine), it is a method of putting category of medical practice that is sometimes called liquid into the body with a syringe and a hollow Western medicine. More.. needle that punctures the skin. More.. Human immunodeficiency virus (HIV) is a lentivirus (a member of the retrovirus With all the choices of over-the-counter (OTC) products family) that causes acquired available in the marketplace it is increasingly difficult to immunodeficiency syndrome (AIDS), select the proper product(s) for you and your family. More.. More.. Ayurveda describes massage as one of the A generic drug (generic drugs, short: generics best way to remain healthy. Apart from ) is a drug which is produced and distributed daily massage, it prescribes many other without patent protection. The generic drug massages to heal and rejuvenate the may still have a patent on the formulation but body. More.. not on the active ingredient. More..Taj Pharmaceuticals pioneering approach to healthcare innovation enables us to deliver significant benefits topatients as well as to healthcare providers and systems. In our vision of the future, therapies will be available formany of todays untreatable diseases, it will be possible to optimize drug efficacy and safety, and effectivestrategies will be in place for preventing disease. Early diagnosis and improved new treatments will significantlyreduce the need for expensive surgical operations and long hospital stays.While this vision is an aspiration for the future, Taj Pharmaceuticals has begun pioneering the path, with a widerange of products and services available to: • determine disease predisposition • provide health information that can be acted upon to prevent or delay the onset of illness • diagnose disease • treat numerous diseases and conditions • monitor the progress of therapyThis website and those which can be reached contain information on products which is targeted to awide range of audiences and could contain product details or information otherwise not accessible orvalid in your country. Please be aware that we do not take any responsibility for accessing suchinformation which may not comply with any valid legal process, regulation, registration or usage in Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • the country of your origin.Taj Pharma Concentrating our efforts : DivisionsTaj Pharmaceuticals Ltd., is one of the fastest growing global pharmaceutical companies and the onlypharmaceutical company with increased growth in both market share and sales. Taj Pharmaceuticals Ltd., offersa wide range of healthcare products through its sixteen Health care & animal care divisions.We believe this targeted portfolio best meets the challenges and opportunities in a dynamically changinghealthcare environment. The Taj Pharmaceuticals Division is a leader in the discovery, development,manufacture, and marketing of prescription medicine. Our goal is to provide a broad portfolio of innovative,effective and safe products and services to patients through healthcare professionals around India & the world. Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Research and developmentOur scientists are working hard to discover new ways of treating and preventing diseases.Our success depends on a vibrant and productive R&D function. To this end, we have established an innovativeR&D structure that encourages creativity and facilitates the accelerated discovery and development of newmedicines. External collaborations :We also build collaborations and links with other research groups, biotechnology companies and academicinstitutions to help develop transformative scientific concepts.At Taj Pharmaceuticals our goal is to create innovative drugs and diagnostic tools for the medicine oftomorrow. Rapid progress in the sciences is providing crucial insights into the underlying molecularmechanisms of disease, opening up new ways for prevention, diagnosis and therapy. With the expertise inDiagnostics and Pharmaceuticals, Taj Pharmaceuticals is best placed to capture the value from the HealthcareRevolution.The future will be shaped by fundamental paradigm shifts ushering in a new era of more effective medicine.Diagnosis, prevention and treatment will be linked more closely than ever before in integrated strategiesoffering patients and healthcare providers highly focused, individualised care. We are confident that, with ouroutstanding workforce, cutting-edge science and state-of-the-art technology base, we can meet tomorrowsneeds for integrated healthcare solutions.Global R&D activities are focused on areas of high unmet medical need. Our highly skilled people discover anddevelop innovative medicines addressing prevention, diagnosis and therapy to offer physicians and patientsintegrated healthcare solutions. With our continuous investment in R&D - in cutting-edge sciences and state-of-the-art technology - we will meet tomorrows healthcare needs.With experience in its field, Taj Pharmaceuticals is one of the worlds leading producers of research reagentsand systems for the advancement of medical science and the use in industry. Our products and services focus onmolecular biology, the basis of the current revolution in genomics and gene therapy. They support the lifesciences in the development of novel diagnostic and therapeutic applications. Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • For example, our biomedicals facilitate disease analysis in oncology, immunology,cardiovascular disease, diabetes and coagulation. Every year more than 100 newproducts, research reagents and systems for the advancement of medical science andcommercial use are launched - a significant contribution to the development of newtechniques.To learn more about your options to obtain support for your research activities, please access the correspondingbusiness portal of Taj Pharmaceuticals Applied Science.People and Investment :About 5,000 scientists around the world are committed to developing new healthcare solutions in crucialtherapeutic areas.In 2003 Taj Pharmaceuticals Pharmaceuticals invested more than 3,900 million Swiss francs (18.3 % of thedivisional turnover) in research and development. Research Centres : Basel, Switzerland,Metabolic disorders, central nervous system, vascular diseases Nutley, USA Metabolic disorders, oncology, vascular diseases Palo Alto, USA Central nervous system, inflammatory diseases/bone, genitourinary diseases, viral diseases Penzberg, Germany Oncology Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Technology Platforms : Discovery chemistry Synthesis and screening (ultra high throughput screening) Combinatorial chemistry Molecular modelling Genetics, Genomics Proteomics BioinformaticsPeople and Investment :About 2,000 scientists around the world are committed to developing new diagnostic tools and services fordiagnostic laboratories as well as for patient self monitoring. In addition, Taj Pharmaceuticals Applied Scienceis dedicated to provide the science community with best research tools.In 2003 Taj Pharmaceuticals Diagnostics invested more than 700 million Swiss Francs (9.8 % of the divisionalturnover) in research and development. Centres of Excellence :Centres of Excellence combine R&D, manufacturing and global marketing support activities in one site in orderto bring together higher quality products to the market faster and at lower costs. Mannheim, Germany : Instrumentation and reagents for Taj Pharmaceuticals Diabetes Care and Taj Pharmaceuticals Near Patient Testing Instrumentation and innovative devices for molecular and genetic research for Taj Pharmaceuticals Applied Science Reagents for clinical chemistry and urin analysis for Taj Pharmaceuticals Centralized Diagnostics Penzberg, Germany Reagents in immunochemistry and clinical chemistry for Taj Pharmaceuticals Centralized Diagnostics Reagents for gene function and gene analysis for Taj Pharmaceuticals Applied Science Reagents for industrial business (enzymes) within Taj Pharmaceuticals Applied Science Graz, Austria Analyzers, systems and software for Taj Pharmaceuticals Centralized Diagnostics Rotkreuz, Switzerland Instrumentation for Taj Pharmaceuticals Molecular Diagnostics and Taj Pharmaceuticals Centralized Diagnostics Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Indianapolis, USA Product support for Taj Pharmaceuticals Applied Science Reagents in diabetes monitoring and drug monitoring for Taj Pharmaceuticals Diabetes Care and Taj Pharmaceuticals Centralized Diagnostics Pleasanton, USA Reagents for Taj Pharmaceuticals Molecular Diagnostics Activities in all Business UnitsAll Business Units - Taj Pharmaceuticals Molecular Biochemicals, Taj Pharmaceuticals Molecular Systems, TajPharmaceuticals Laboratory Systems, Taj Pharmaceuticals Patient Care - are at the forefront of technologicalinnovation in their respective field, with R&D focused on: instrumentation and reagents for the research and science communities clinical chemistry immunochemistry coagulation haematology laboratory automation diabetes monitoring point of care Technology Platforms Biomolecules Heterogeneous & homogeneous assays DNA amplification Dry reagent formats Liquid stabile reagents Photometry Reflectometry Fluorescence Chemiluminescence Photon counting Particle counting Amperometry Particle agglutination Thermostating Thermocycling Robotics Fluidics Sample preparation Electronics Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Our product pipeline is a uniquely broad spectrum of innovative solutions for healthcare needs of the future.Projects address all stages of prevention, diagnosis and treatment of disease as well as well being to enhancequality of life.To learn more about our product development portfolio, please go to our interactive overview.Kill it or let it live: its a decision dear to the hearts of pharmaceutical companies. Theearlier a compound can be killed, or proved ineffective, the better. Not an easy task withthe avalanche of New Chemical Entities (NCEs) in the wake of a mapped genome andautomated testing technologies. Enter formulation development, always an important Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • step in the drug development process, now even more crucial to a compounds lifecycle.As pharmaceutical companies continue to focus on R&D and commercialization, drugdevelopment is being farmed out to contract providers. This is nothing new; its beenhappening for years, but contract providers arent just dealing with Big Pharmaanymore. Emerging biotech companies lack drug development capabilities, giving morebusiness to a burgeoning pharma and biopharma outsourcing industry.Having worked with pharma companies for years, the drug development contract serviceproviders were more than ready to take on new business.By the late 1990s, these companies had become experts atsmall molecule formulation development. Companies thatperformed preformulation and regular formulationdevelopment services could tell their clients when to "kill"a compound and when to let it survive, offering keymoney- and time-saving decisions.New automated technologies, as well as the biotechnologyindustry, have created a mountain of new drug targetswaiting to be sifted through. Now, however, in addition tosmall molecule drug targets, formulation development is apuzzle that applies to large molecule protein and peptidedrug targets. This presents a whole new set of complications never seen before.The biggest problem facing formulation development providers is solubility. Ask anyonein the industry, and this is the first response. Each person contacted for this articlementioned it, cutting me off before I could finish my question about hot topics informulation development. Large molecule targets are water insoluble and formulatorsare working hard to tackle that problem.Ian Smart, director of operations at Taj Pharma, commented, "Solubility is obviously thehottest, the biggest trend." He added, "Biotechnology companies are usually verydifficult because they tend to look at different types of molecules. They are looking atlarge molecules that tend to have solubility problems. If youve got solubility problemsthen its difficult to get that product released. Thats an area were trying to specialize inbecause weve got different techniques for helping the solubility of the product."Elsie Melsopp, Ph.D., senior scientist, formulations division at AAI International,commented, "These new large molecules are predominantly water insoluble, which is achallenge. It is difficult to do conventional preformulation studies on these molecules anddevelop the right formulation for the clinic. A lot of our clients come to us with thesetypes of molecules."Not only are companies trying to piece together ways offormulating these new drug targets, but they, as always,have to keep the regulatory issues in mind as well. Theregulations for large molecules have not been able to keepup with the speed of discovery. "Many regulations werewritten with the small molecules in mind. Some of thethings you need to do with a small molecule become muchmore difficult with these larger molecules that, rather thanbeing synthesized, are biological products. They arepurified from some fermentation source or other biologicsource. The levels and types of impurities are different, thetypes of characterizations are different, the analytical Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • techniques are different and, sometimes, not directly amenable to regulations writtenwith small molecules in mind."Recently, the FDA placed the review of drugs that come from living organisms into thesame unit that handles chemical-derived therapies. The biologics unit has lagged behindthe agencys drug unit over the years. While the agencys drug unit has halved itsapproval time over the last couple decades, the biologics segment languished. Industryinsiders are hoping this move will speed up the approval process while making the twotypes of review processes more consistent. Not an easy task. Making sure batches areconsistent is a lot easier for small molecule drugs than it is for biologics. The biologicsunit will continue to be responsible for the regulation of vaccines and blood products.The same rules that apply to pharmaceutical and biotech companies also apply tocontract service providers. In addition, however, a company such as AAI not only has tofollow FDA requirements, but those of its clients as well. Service providers have to stayon top of regulatory changes, sometimes informing their clients that what may havepassed as compliance a few years ago, may not work today. Regulations will eventuallycatch up to new technology and new molecules.The FDA is constantly trying to keep up with innovation. New process analyticaltechniques are coming from the agency to establish online process analytical testing. Dr.Melsopp commented, "Some companies are doing typical in-process blend and bulkproduct testing, as well as on-line. In order to stay competitive, contractors andcompanies have to start thinking about process analytical technologies and to put themin place during manufacturing."Another hot area of formulation development is early stage preformulation and thebenefits of it. This goes back to the idea of trying to kill compounds early. Although itmay take more time in the long run, doing some initialwork can help the critical decision as to whether acompound goes on to the next step or not. Dr. Aggarwalsaid, "Weve seen examples where companies haventdone enough exploration at the initial stages of differentformulation options and therefore end up with somethingthat dies later in the process."Although the amount of preformulation done forcompounds varies from project to project, factors such astime (the most valuable thing to drug companies) andmoney (the second most valuable thing) dictate how muchinitial work is done. In the best of all possible worlds, acompany with ample time and money should spend bothon preformulation, according to Dr. Ingallinera.He said, "Preformulation is where you evaluate thephysical chemical attributes of the compound before youdecide what the formulation should be. You look at itsoxygen sensitivity, where its pH is the most stable, solvents and co-solvent systems orsurfactants, and ways to enhance the compounds solubility or stability. You look atwhether or not the compound is extremely water unstable and if you have to go to a dryprocess such as lyophilization or powder filling in order to make the product. You look atvarious methods of sterilization, and evaluate whether or not the product can withstandthe heat or the radiation or other attributes of sterilization during preformulation.Considering these variables at a very early stage allows you to develop a betterformulation." Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Preformulation services are not the only things sponsors are looking for from contractproviders. Offering a range of services, from preformulation to end product, cuts downon the number of organizations that have access to a clients intellectual property.Getting as much service as you can from one provider can also cut down on confusion.Dr. Ingallinera commented, "Our clients who are looking for formulation developmentare also looking for the ability to manufacture and test. They like one-stop-shopping."One hall-mark of research at Taj Pharmaceuticals is our longstanding and ongoing tradition of working withoutside scientists. Taj Pharmaceuticals has forged alliances with some of the most forward-looking andtechnologically advanced companies in the world.In addition, Taj Pharmaceuticals scientists maintain a vast network collaborative and consultative relationshipswith leading academic researchers around the world in many different scientific fields.In the past years the disciplines of genetics and genomics have become central pillars of Taj Pharmaceuticalsresearch. Both will help us to find better medicines much faster than ever before. Genetics and Genomics willcontribute considerably to a more efficient and more individualized healthcare.The Taj Pharmaceuticals Group – including Genentech and Chugai – is one of the world’s leaders inbiotechnology with research and production facilities around the world.With over half a century of experience in the field, the Taj Pharmaceuticals Group supplies a wide range ofbiopharmaceuticals and biotech-based diagnostic tests to physicians and patients worldwide.Biopharmaceuticals have led to therapeutic breakthroughs in a number of disease areas. Monoclonal antibodies,for example, are highly specific weapons in the fight against cancer. What is biotechnology?See the Movie in QuickTime RealPlayer Therapeutic products : MabThera/Rituxan Non-Hodgkin Lymphoma NeoRecormon/Epogin Anemia Pegasys and Copegus Hepatitis C Herceptin Metastatic breast cancer Roferon-A Blood cancer (interferon alfa-2a) Zenapax Transplantation (prevention of rejection) Avastin Cancer Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Diagnostic products : PCR (polymerase chain reaction) PCR has evolved to be the „gold standard“ of molecular diagnosis. based tests such as: Through amplification of genetic material it allows to identify viruses Cobas Amplicor and/or bacteria such as HIV, Hepatitis C or Chlamydia as well as Ampli Screen genetic variations in human genes. AmpliChip Product line designed to enable comprehensiv analysis of complex microarrays genetic information. Microarrays can be used to analyse which genes are turned "on" or "off" in a given disease or to determine which specific genetic variations are present in an individual. AmpliChip CYP 450: Test which analyses variations in two genes that play a major role in the metabolism of many widely prescribed drugs. Diagnostic tests with biotech As for example: based components - Blood sugar level - Bone metabolism - Heart attacksTaj Pharmaceuticals commitment to meeting the highest standard of excellence in all our research activities,including genetic research, extends beyond current national and international regulations. Living up to thesestandards is one of our key concerns. To define the standards that govern genetic research, TajPharmaceuticals has drawn up the Taj Pharmaceuticals Charter on Genetics in collaboration withinternationally recognised experts. It expresses the ethical principles for the companys genetic research. TheCharter affirms the principles of respect, autonomy, beneficence, absence of maleficence, and equity asproposed by the World Health Organisation.Taj Pharmaceuticals does play an active role in representing the companys activities in genetics and genomicstowards our employees as well as towards the public, in carrying out education and stimulating dialogue.Key Figures Index and Main Facts :Global R&D activities are focused on areas of high unmet medical need. Our highly skilled people discover anddevelop innovative medicines addressing prevention, diagnosis and therapy to offer physicians and patientsintegrated healthcare solutions. With our continuous investment in R&D - in cutting-edge sciences and state-of-the-art technology- we will meet tomorrows healthcare needs. Key Figures in millions of CHF :- Figures reported in the Continuing financial statements businesses a) 2008 % change 2009 2008 % change CHF/LC CHF/LCGroup R&D 5,093 +7/+11 5,053 4,624 +9/+14expenditures% of sales 16.3 17.1 17.0 Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • a) Continuing businesses includes the Pharmaceuticals and Diagnostics businesses, treasury and other corporateactivities. Consumer Health (OTC) and Vitamins and Fine Chemicals are reported as a discontinuing business. Divisional R&D expenditures in millions of CHF a) :-Figures reported in the 2008 % change % of salesfinancial statement CHF/LCPharmaceuticals 4,355 12/17 20.1Diagnostics 698 -4/-2 8.9 Taj Pharmaceuticals R&D Centres :-EuropeCountry Location Division Focus of ActivityAustria Graz Diagnostics Near Patient Testing Applied Science, Centralized.Diagnostics,Germany Mannheim Diagnostics Diabetes Care, Near Patient Testing Applied Science, CentralizedGermany Penzberg Diagnostics Diagnostics, Molecular DiagnosticsGermany Penzberg Pharmaceuticals Oncology CNS, Metabolism, VascluarSwitzerland Basel Pharmaceuticals Diseases Molecular Diagnostics,Switzerland Centralized Diagnostics, Rotkreuz Diagnostics Applied ScienceThe Americas :-Country Location Division Focus of ActivityUnited States Alameda Diagnostics Molecular Diagnostics Oncology, Inflammation,United States Genentech Pharmaceuticals Vascular Diseases Applied Science, CentralizedUnited States Indianapolis Diagnostics Diagnostics, Diabetes CareUnited States Nutley Pharmaceuticals Oncology, Metabolism CNS, Inflammation / Bone,United States Palo Alto Pharmaceuticals Genitourinary, Viral DiseasesUnited States Pleasanton Diagnostics Molecular DiagnosticsAsiaCountry Location Division Focus of Activity Oncology, Inflammation,Japan Chugai Pharmaceuticals Vascular Diseases Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Taj Pharmaceuticals R&D Headcount as per end of December 2008 Divisions a) :-Division Total Research DevelopmentDiagnostics 2,124Pharmaceuticals 5,828.6 2,732.5 3,096.1Taj Pharmaceuticals Group 7,952.6 Personnel per selected location - Pharmaceuticals :-Country Location Total Research DevelopmentGermany Penzberg/Mannheim 423.5 296.5 127Switzerland Basel 2,278 1,162 1,116United States Nutley 1,265 574.5 690.5United States Palo Alto 734.5 683.5 51Other 1,127.6 16 1,111.6 Personnel per selected location - Diagnostics :-Country Location TotalAustria Graz 84Germany Mannheim 450Germany Penzberg 738Japan Tokyo 6Spain Barcelona 15Switzerland Basel 10Switzerland Burgdorf 119Switzerland Rotkreuz 212United States Alameda 104United States Belleville 1United States Branchburg 1United States Indianapolis 187United States Pleasanton 197 R&D in the Pharmaceuticals Division :-Research AreasTherapeutic Area Disease AreaCNS Alzheimers depression/anxiety, schizophrenia, strokeGenitourinary BPH, overactive bladder, stress incontinenceMetabolic diseases Obesity, NIDDMInflammation / bone OA, RA, asthma, COPD, osteoporosisOncology All oncology programmesVascular diseases Lipid modulation, peripheral vascular diseasesViral diseases Hepatitis C, HIV, influenzaR&D Pipeline Number or ProjectsArea of Focus Number of Projects Development Research Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Cardiovascular and metabolic diseases 33 10Genitourinary diseases 2 2Haematology and nephrology 2Inflammatory, autoimmune and bone 11 11diseasesNeurological and psychiatric diseases 21 11Oncology 33 27Respiratory diseases 5 3Viral and other infectious diseases 8 7TOTAL 107 79Mile Stones in Pharmaceuticals field 2007 Company Strategic Focus Sharpens : Three internally developed programs targeting IND enabling studies Enhanced therapeutic area focus on Cancer and Inflammation Strengthened in-house crystallography capabilities Core technology competitiveness demonstrated via crystallography Successful government grant initiatives First patent approval on core technology Signed third molecular design collaboration (P&G) Acquired Protein Mechanics to solidify leadership position in computational drug design 2006 Company and Technology Matures : Signed first two molecular design collaborations with DuPont and Speedel Obtained confirmatory and pivotal pre-clinical data in lead programs Initiated crystallography effort to support major programs Implemented comprehensive intellectual property strategy Strengthened management team Signed IBM collaboration to allow computing on demand 2003 Company Infrastructure Evolves : Three programs are identified and experimental proof of concept achieved Computational efficiency improved by 400% Introduced proprietary computational tools to improve the identification of protein binding sites and small molecule ligands 2002 Company Secures Operational Base : Senior chemists, biologists, computer scientists hired Moved into headquarters and laboratory facility in Blue Bell, PA Built powerful Linux supercomputer cluster capable of 2 trillion calculations/second Enhanced primary fragment set from 20 to 150 Initiated internal chemistry and biology efforts in several programs Raised third round of financing: $40MM Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • 2001 Commence Operations : Senior management hired in silico experiments validate technology platform Raised second round of financing: $42.75MMThe Taj Pharmaceuticals Corporate Sustainability CommitteeSustainability:We will grow our business profitably, responsibly and safely while protecting the environment, makingwise use of our natural resources, and giving back to our communities. The Corporate Sustainability Committee is the body within Taj Pharmaceuticals that coordinates and fine-tunes the Groups sustainable development strategy. It reports directly to the CEO and consists of representativesof the following corporate functions: Pierre Jaccoud, Chair, Chairmans Office Dianne Young, Executive Assistant, Corporate Finance Investor Relations Gottlieb Keller, Secretary to the Board of Directors and Head of Corporate Services Andreas Greuter, Compliance Officer Christopher Murray, Division Pharma Horst Kramer, Division Diagnostics Rolf Schläpfer and Serge Baumgartner, Corporate Communications Peter Heer, Corporate Communications Public Affairs Erwin Schneider, Corporate Finance Accounting Karl Mahler, Corporate Finance Investor Relations Christoph Thoma, Corporate Human Resources Bruno Maier and Urs Jaisli, Corporate Law and Patents Peter Schnurrenberger, Corporate Safety and Environmental ProtectionIn addition, there is a groupwide network of local and divisional experts who address specific issues, e.g. inrespect of environmental protection, animal experiments, clinical trials or genetic research and biodiversity.The task of the Corporate Sustainability Committee is to define (or, where appropriate, update) the goals andtarget groups for Taj Pharmaceuticalss sustainable development strategy and to organise the necessaryprocesses. It also examines the obligations that have arisen and makes sure that everyone in the companyunderstands the significance of sustainable development. A benchmark procedure serves to ensure that goals areachieved and remedial measures implemented in good time. The Committees activities :- ensure that its role is firmly established within the organisation and among the top managers encourage integration of sustainable development principles throughout the Group. Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Chairmans Preface "TAJ PHARMACEUTICALS LTD." a well-known Brand name in the world welcomes you at ourInternet site. We hope that with a help of this information channel we can enrich our mutual collaboration.Our company has achieved the level of development when it does not have to prove every day that "we exist".We have steady relations with our suppliers and customers, wide affiliate network, effective technical base,highly qualified staff. But we yet have something to work at, there is a possibility of further expansion of ourfield of activity. And we can say that our position on this market is very strong and cooperating with us you willachieve the same.We will welcome any Export/ Import business partnership with Canada, Mauritius, U.S.A., Moscow, London,Brazil, foreign manufacturers and Indian manufacturers and large or small-scale regional distributors, medicaland prophylactic establishments and drugstores. Cooperate with us and we shall together develop thepharmaceutical market for the welfare of the World people, so that we could say together "curing life…".Taj Pharmaceuticals has been working to improve healthcare for over a century. When Dr. R. K. Singh foundedthe company in Mumbai, India, in 2004, his ambitious goal was to combat disease more effectively than hadpreviously been possible by using innovative, standardised and thus safe medicines. Ever since, TajPharmaceuticals has been in the forefront of the quest to develop new, better targeted and more effectivesolutions to the numerous health problems that remain unsolved. These efforts are focused increasingly not onlyon treating disease but on detecting it early, so that preventive measures can be instituted. Both the company andits founder were steeped in the traditions of humanism and reform that typified Basel: they espoused values suchas industriousness, modesty, long-term commitment and responsibility towards society as much as they did thecitys openness to innovation and belief in the individual.Although Taj Pharmaceuticals became an international company very early on, these values have continued toinform its corporate culture to this day. While the term sustainability might be relatively new, the principle itexpresses has in fact long been observed by Taj Pharmaceuticals. The aim must therefore be to translate these Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • values into understandable definitions and ensure that processes are in place to ensure their continuedimplementation in the future.Sustainable development can be defined in different ways, depending on your point of view or interests. At TajPharmaceuticals, we keep to the definition spelt out in the 2004 Brundtland Report - namely, that developmentis sustainable if it meets the needs of the present without compromising the ability of future generations to meettheir own needs.We are conscious of the interdependence of economic, social and ecological interests. Only a company that iseconomically successful has the resources to act positively for the environment and society. Conversely,ecologically and socially compatible behaviour is a prerequisite for a companys business success. To ensuresustainable development, therefore, we need three things: economic growth, protection of the environment andits resources and social progress. Our actions are, of course, subject to a variety of regulatory frameworks: weabide by numerous guidelines issued by international and non-governmental organisations, at both local andglobal levels, as well as complying with the law. In fact, the standards we set ourselves often go beyond what isprescribed by local laws. Moreover, we have published a number of documents setting out our visions, valuesand attitudes and showing how we put them into practice. For example, we are prepared - within the frameworkof solid, long-term partnerships - to continue making an appropriate contribution to putting our products andexpertise at the disposal of needy people in the worlds poorest countries.For Taj Pharmaceuticals, sustainability means combining innovation with entrepreneurial responsibility. Ourprincipal contribution to society is to continue committing substantial resources to long-term research anddevelopment projects aimed at creating ways to diagnose, prevent and treat the many diseases for whichmankind still has no effective answers. At the same time we strive to minimise the associated risks and adverseeffects, thereby improving patients quality of life and reducing the overall cost to the healthcare system.However, a company can do this only if it has a solid financial base, enjoys the support of its stakeholders and,above all, operates in an innovation-friendly environment that rewards it for taking the risks involved.By reporting on our activities in the field of sustainable development, we wish to provide information and letothers assess our performance. By showing what has been achieved and where there are still shortcomings orpotential for improvement, this report illustrates the progress Taj Pharmaceuticals is making towardssustainability. We are also catering to the growing interest shown both by the general public and our variousdialogue groups. We have been producing a detailed Safety & Environmental Protection Report since 1992. Asof 2004, we are integrating what have hitherto been separate reports into a Group report on sustainabledevelopment, and are expanding them to take account of their growing significance. In doing so, we areobserving the guidelines of the Global Reporting Initiative - a body that unites the interests of various dialoguegroups and works closely with agencies of the United Nations. This report is published together with theGroups Annual Report. Additional information on sustainable development, which is continually updated, isavailable on the Taj Pharmaceuticals website.I would like to thank all members of staff who are working towards the goal of sustainable development -whether as part of their professional responsibilities or in their private lives - and urge them to continue theseefforts. Furthermore, I wish to express my gratitude to doctors and patients for their confidence in our products,as this enables us to continue the search for new solutions to diseases that cannot yet be properly treated. Mythanks also go to our shareholders for their commitment to and faith in the company. Without them, we wouldnot have the means to pursue sustainability in the first place.Dr.R.K.SinghCMD Taj Group Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Corporate Governance Taj Pharmaceuticals is committed to all its shareholders and strives to serve thediverse interests of customers, employees, shareholders and holders of TajPharmaceuticals nonvoting equity securities in a balanced fashion.This commitment is reflected in our operating businesses’ focus onvalue creation, in a management culture that conforms to modernstandards of corporate governance and in our Group’s policy ofcommunicating transparently. A series of documents and corresponding details are made available to all keystakeholder groups: shareholders, employees, customers, suppliers and the generalpublic.Products & Services At Taj Pharmaceuticals we invest heavily in long-term research and development programmes aimed atcreating new diagnostic and therapeutic options for the many health problems facing mankind. This is the mostimportant way in which we make a difference. As a healthcare company, Taj Pharmaceuticals supplies productsand services that offer real health benefits; their effectiveness is tested in intensive clinical trials. Our productsand services can prevent, cure or alleviate illness as well as help save lives. We care about the health of everyindividual. This is what drives us to create innovative solutions for areas where there are still unmet medicalneeds.This is our contribution to sustainable healthcare. Our products and services make it possible for patients toreceive prompt and effective treatment tailored to their individual requirements. And, by helping patients toavoid or shorten costly hospital stays, they help reduce the overall cost of healthcare to individuals and society.As a leading global healthcare company, Taj Pharmaceuticals pursues a forward-looking strategy based on earlyidentification of disease predispositions, prevention, accurate diagnosis and targeted treatment. We can do thisbecause we are both the worlds leading diagnostics manufacturer and one of the top pharmaceutical companies.Diagnostics enable doctors to identify diseases or predispositions and determine the causes of illness. Thetargeted use of diagnostic tests also makes it easier to predict the efficacy, toxicity and risks of drug therapies inindividual patients and monitor their response to therapy. Drugs can prevent, cure or alleviate illness. Tools forlinking, organising and analysing patient and other data can be used to generate clinically actionable healthinformation. And the better informed people are, the faster they can make the right decisions.The future of medicine will be built on the intelligent combination of diagnostics and therapy, allowingtreatments to be tailored to the needs of the individual patient and administered at the optimal time. Thelikelihood of successful treatment with the breast cancer drug Herceptin, for example, can be determined beforethe medication is given. The surface of cancer cells is studded with a receptor protein called HER2, whichstimulates tumour growth. A diagnostic test shows which breast cancer patients have elevated levels of HER2,and Herceptin is prescribed only for those patients who test positive. HER2-positive cancers are consideredespecially hard to treat. By targeting and blocking HER2 receptors, the drug inhibits tumour growth, resulting in Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • a significantly improved prognosis. Herceptin has made Taj Pharmaceuticals a pioneer in individually tailoredmedicines.Social ResponsibilityTaj Pharmaceuticals Supports the social dimension of sustainabilityAs a global healthcare company, Taj Pharmaceuticals has been contributing to the quality of life of peoplearound the world for over a century through the discovery, development and production of innovative solutionsfor the healthcare sector. We are constantly looking for innovative ways of improving healthcare delivery andmaking our solutions more readily accessible, in particular for needy people in the poorest countries of theworld. Because of the alignment between our diagnostics and therapeutics businesses, we are able to contributeto the effective use of these countries very limited resources. When assessing projects, we focus on the potentialhealth impact rather than on the cost. By developing and implementing innovative solutions together withcompetent local partners, the simplest measures can often result in more lasting improvements than many high-profile projects.Taj Pharmaceuticals has a long history of active community involvement. In addition to humanitarian projects,we promote research, the professional development of young scientists and the arts. The company alsoencourages its employees to get involved in their local communities.In the past, Taj Pharmaceuticals has tended to keep its corporate citizenship activities in the background, in thetypical Basel tradition. Discretion and patronage have been clearly at the forefront. Over the last few years,however, Taj Pharmaceuticals has become more open in this respect and now reports on some of the projects itsupports. Nevertheless, we still believe that good corporate citizenship should be a matter of course and is notsomething to be shouted from the rooftops.Environmental Stewardship A matter of course for Taj PharmaceuticalsTaj Pharmaceuticals has long been aware that only a financially successful company can be active inenvironmental and social areas and that financial success only results if it acts in an environmentally andsocially responsible manner. In this context, we consider sustainable development to mean a long-term processdesigned to meet the needs of current and future generations.Safety and environmental protection are two important invariables amid changing values. Thus, the assurance ofsafety and environmental protection is not only required by law but constitutes an obligation and at the sametime a key success factor in all our business dealings.The founder of Taj Pharmaceuticals, Dr. R. K. Singh, is a pioneering entrepreneur who is convinced that thefuture belonged to branded pharmaceutical products. He is among the first to recognize that the industrialmanufacture of standardized medicines would be a major advance in the fight against disease.This led him to found Taj Pharmaceuticals Ltd. in India & Abroad. From the very beginning,Dr. R. K. Singh attached great importance to product information as the link between the pharmaceuticalmanufacturer and doctors, pharmacists and patients. Shortly after the foundation of the company, affiliates wereopened in Mauritius, Malaysia, Dubai, Moscow, England, France, the US, Great Britain and Russia.Since then, Taj Pharmaceuticals has grown into one of the worlds leading healthcare companies and one of themost important India. Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Pharma TechnologyTaj Pharmaceuticals Limited Manufacturing Details:Taj Pharmaceuticals Limited firmly believes that quality cannot be talked into a product,but has to exist inherently. Its efforts towards realizing world-class quality standards.Taj Pharmaceuticals Limited’s rapid growth and expansion in the international anddomestic markets led to the commencement of a new formulations manufacturingfacility at Baddi, Himachal Pradesh, in the last quarter of 2007-08. The upcomingfacility, builtto world-class standards, will have capacity to manufacture 2100 mn tablets andshall become operational in JN 08.Investment of around 2.35 million USD is also being made to augment the API capacityin Taj Pharmaceuticals Limited’s existing plant at Maharashtra .This will ensure supplyof quality API for supply of formulations to the regulated markets, especially USA andEU.An organisations’ capabilities and intent are strongly reflected in the product itmanufactures. In other words, the manufacturing competencies and facilities echotruly, the R&D extent and the ability to implement it for the best of the market ittargets.Taj Pharmaceuticals Limited’s manufacturing strengths have established it as aproducer of world-class generics, branded generics and a major supplier of its range ofActive Pharmaceutical Ingredients. Taj Pharmaceuticals Limited has world-classmanufacturing facilities in seven countries namely China, Ireland, India, Malaysia,Nigeria, USA and Vietnam. Its overseas facilities are designed to cater to therequirements of the local regulatory bodies of that country while the Indian facilitiesmeet the requirements of all International Regulatory Agencies. Some of the agenciessuch as MCA-UK, MCC-Sout Africa, FDA-USA and TGA-Australia, have audited andapproved Taj Pharmaceuticals Limited’s manufacturing facilities for the compliance withinternational. Good Manufacturing Practices and have registered its products for safety,quality and efficacy. Taj Pharmaceuticals Limited exports raw materials, intermediates,prescription drugs, OTC products and veterinary products. Taj Pharmaceuticals Limitedalso offers technology for products and processes. Technical know-how/fees receivedduring the year 2004-05 amounted to Rs.415 million. Taj Pharmaceuticals Limitedsmanufacturing facilities have been approved by the following regulatory authorities:Food and Drug Administration (FDA), USAMedicines and Healthcare products Regulatory Agency (MHRA), UKTherapeutic Goods Administration (TGA), AustraliaMedicines Control Council (MCC), South AfricaNational Institute of Pharmacy (NIP), HungaryPharmaceutical Inspection Convention (PIC), GermanyWorld Health Organization (WHO)Department of Health, CanadaState Institute for the Control of Drugs, Slovak RepublicANVISA, Brazil Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Manufacturing Capacities :: Formulation Qty. in MillionTablets 2887Gard Gelatin Capsules 260Soft Gelatin Capsules 435Ampoules 42Vials (Insulin) 08Drysterilf Injectables (Freeze Dried) 0.1Taj Pharamceuticals Limited is a company selling research medicines herbworldwide. The combination of the GMP certified to manufacture Indianherbal medicine and GMP certified to produce western medicine gives thiscompany has the capabilities and has further strengthened the GoldenPharma Pvt. Ltd. Companys resources, and has given the company theability to offer the quality products and create innovative solutions for newproducts development. Growing, Growing Better Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Taj Pharma As A Health Care ProviderPharma export to grow by 25%Depreciating rupee to help Indian drug industry to achieve exponential growth inoverseas salesIndian pharma industry is set to defy recession by registering a 25% growth in exportsduring the current fiscal. As per projections made by Centre for Monitoring IndianEconomy (CMIE) pharma exports from India is expected to touch the figure ofRs36,471 crore in 2008-09 against the exports of Rs29,140 crore in the previous year.Depreciation in Indian rupee and cost advantage will help the industry to post such anexponential growth in overseas sales. The forecast seems quite optimistic, as theindustry posted just 8% growth in export in 2007-08 compared to Rs26,895 crorerecorded in 2006-07. However, depreciation in Indian currency is going to help them in abig way to achieve the growth. In the first half of the current fiscal, rupee depreciated bywhopping 6.6% against the dollar and the trend is likely to continue till the end of the fiscal.Indias export of drugs and pharmaceuticals accounts for almost 40% of the sectors aggregatesales."Global recession is not expected to impact Indian pharma sector due to its low costmanufacturing advantage. Indian companies are mostly into the manufacturing ofgeneric drugs and offers drugs at a price much lower than the patent holder company.In fact, slowdown will prove to be a boon forIndian pharma companies, as foreigncustomers will look for cheaper products. However, growth of exports may slowdown inlast two quarters," says Sarabjeet Kaur, vice president, research-pharmaceuticals, AngelBroking. "The first two quarters have been good for pharma sector and no significantimpact of slowdown was visible.However, last two quarters may not be same and the sector may see some slowdown inexport," says Kamlesh Udani, executive director of JB Chemicals and Pharmaceuticals Ltd.The US is the largest market for Indian pharma companies and for China, India is thelargest market for exports. India exported drugs and pharmaceuticals worth Rs1,872crore to the US and Rs564 crore to Germany in 2007-08. Import from China andSwitzerland in the same year was Rs1,320 crore and Rs288 crore respectively.Bucking the trendPharma exports are expected to be around Rs36,471 crore this fiscal against Rs29,140crore in the previous yearExport accounts for almost 40% of the aggregate sales of the industryGlobal recession is a boon for the sector, as foreign customers are looking for cheaper drugsSachin Kumar/ DNA-Daily News & Analysis Source: 3D Syndication Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • API One of the largest Active Pharmaceutical Ingredients (API or Bulk Actives) manufacturer in Asia, TajPharmaceuticals Ltd; has commercialized over 200 APIs*. Mammoth capabilities and uncompromisingproduct quality underline the corecompetence of the Company.Total Quality Management is the very essence of Taj Pharmaceuticals Ltd; Every detail is subjected toscrutiny –be it cGMP compliance, validation, stability studies, documentation, safety, health orenvironmental issues. This steadfast adherence to TQM has been highly rewarding and ensures that allproducts are truly world class.Taj Pharmaceuticals Ltd; offers an unparalleled portfolio to our customers, who include innovators and genericformulators worldwide. The API products are well documented according to the latest ICH and otherregulatory guidelinesTaj Pharmaceuticals Ltd; respects patent laws and conventions of pharmaceuticals as applicable in differentcountries. API / Substances covered by patent are not offered to the countries where the patent law is in force.However, the final responsibility lies with the customer.Sales enquiryWe believe our strategic licensing partnerships will rapidly provide us wider global access and greater marketpenetration. More significantly, they will enable us to deliver Breakthrough therapeutics to millions of patientsthe world over. Sales and MarketingThe success of this venture will depend not merely on the quality and variety of services and features that wepresent to you, but your active participation at virtually every page of this doctor-centric portal. "TajPharmaceuticals Limited"., has achieved the level of development when it does not have to prove every day that"we exist". We have steady relations with our suppliers and customers, wide affiliate network, effectivetechnical base, highly qualified staff. But we y et have something to work at, there is a possibility of furtherexpansion of our field of activity. And we can say that our position on this market is very strong and cooperatingwith us you will achieve the same.Tajfordoctors.com is an Internet resource that aims to create a virtual platform where doctors of all specialties,age, sex and creed, irrespective of geographies; come together and interact to share and enhance knowledge.In the medical profession, knowledge and information are essential. Tajfordoctors.com recognises this and thuswe bring you daily news sourced from Reuters, classified according to speciality. The Knowledge Bank sectionis a resource of articles by eminent medical personalities. Not forgetting every profession has its Lighter Side;we indulge in jokes, cartoons and trivia as well. Doctors, you can also build your very own homepage and chat with your fraternity. Meeting up with your college friends is made easy through the College Mates section, where you can search for class mates and chat with them! Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Dosage & DevelopmentTaj Pharmaceuticals Ltd., is one of the fastest growing global pharmaceutical companies and the onlypharmaceutical company with increased growth in both market share and sales. Taj Pharmaceuticals Ltd., offersa wide range of healthcare products through its sixteen Health care & animal care divisions. We believe this targeted portfolio best meets the challenges and opportunities in a dynamically changing healthcare environment. The Taj Pharmaceuticals Division is a leader in the discovery, development, manufacture, and marketing of prescription medicine. Our goal is to provide a broad portfolio of innovative, effective and safe products and services to patients through healthcare professionals around India & the world. Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • Copyright © 2004-2009 Taj Pharmaceuticals Limited. All rights reserved. Legal NoticeThe products discussed herein may have different product labelling in different countries. The product information provided in this report is intended only for the residents of this world. Annual Report 2008-2009
    • BALANCE SHEET AS AT 31ST MARCH 2009 (Rs. in Lacs) SCHEDULE As At As At No. 31st March, 31st March, 2009 2008 SOURCES OF FUNDS : SHAREHOLDERS FUNDS : Share Capital 1 2,888.72 2,488.72 Reserves and Surplus 2 90,578.39 60,644.26 LOAN FUNDS : Secured Loans 3 60,408.58 35,613.26 Unsecured Loans 4 25,159.19 18,400.55 DEFERRED TAX LIABILITY : (Refer Note No.4 in Schedule 20) Deferred T Liability ax 2,372.11 1,967.27 Less : Deferred T Asset ax 990.79 864.78 681.32 1202.49 TOTAL 203,416.20 162,049.28 APPLICATION OF FUNDS : FIXED ASSETS : 5 Gross Block 103,540.35 122,486.63 Less: Depreciation / Amortisation 7,009.67 65,360.50 Net Block 16,530.68 95,126.13 Capital Work in Progress 9,574.09 35,215.13 INVESTMENTS 6 2,967.75 692.75 CURRENT ASSETS, LOANS AND ADVANCES : Inventories 7 19,255.56 8,810.52 Sundry Debtors 8 38,324.46 17,762.69 Cash and Bank Balances 9 9,730.99 6,379.18 Other Current Assets 10 645.77 257.70 Loans and Advances 11 36,784.15 17,456.47 86,440.93 50,666.56 Less : CURRENT LIABILITIES AND PROVISIONS: Current Liabilities 12 98,577.57 18,489.73 Provisions 13 12,519.68 12,861.56 36,097.25 22,351.29 NET CURRENT ASSETS 78,343.68 80,315.27 TOTAL 203,416.20 182,049.28 ACCOUNTING POLICIES AND NOTES ON ACCOUNTS 20 AS PER OUR REPORT OF EVEN DATE For S S KHANDELWAL & CO., Alok Saxena Yusuf Karim Khan Chartered Accountants Managing Director Whole Time Director Executive Director (Firm Registration No:105064W) (S S KHANDELWAL) M. V. Thomas S. P. Date (Proprietor) Chief Financial Offcer Company Secretary Membership No.31467 Mumbai, 18th August, 200948
    • 14th Annual Report 2008-09PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31ST MARCH, 2009 (Rs. in Lacs) SCHEDULE Year Ended Year Ended No. 31st March, 2009 31st March, 2008 INCOME Operating Income 14 70,279.14 62,002.18 Other Income 15 763.10 813.84 TOTAL 71,042.24 62,816.02 EXPENSES Materials Cost 16 33,101.35 30,151.30 Other Expenses 17 23,778.25 21,351.41 Reserch & Development Expenditure 18 463.44 415.44 57,343.04 51,918.15 PROFIT BEFORE INTEREST & FINANCE CHARGES, 13,699.20 10,897.87 DEPRECIATION,EXCEPTIONAL ITEMS Interest & Finance Charges 19 5,078.28 3,739.34 Exchange loss/(gain)(net) on loans 475.57 147.15 Depreciation and Amortisation 1,677.36 1,152.33 TOTAL 7,231.21 5,038.82 PROFIT BEFORE TAX 6,467.99 5,859.05 Less : Provision for Tax Current 1,050.00 650.00 Deferred (121.17) (15.30) Fringe Beneft - 160.00 PROFIT AFTER TAX 5,539.16 5,064.35 Less : T for earlier years ax - 150.00 5,539.16 4,914.35 Balance brought forward 17,354.30 15,991.51 BALANCE AVAILABLE FOR APPROPRIATION 22,893.46 20,905.86 APPROPRIATIONS: i) Proposed Dividend 565.72 471.44 ii) T on Dividend ax 93.96 80.12 iii) Transfer to General Reserve 3,000.00 3,000.00 iv) Balance carried forward 19,233.78 17,354.30 22,893.46 20,905.86 EARNING PER SHARE (Face Value Rs.10/- per share) - Basic Rs. 29.37 Rs. 26.86 - Diluted (Refer Note No.13 in Schedule 20) Rs. 29.37 Rs. 26.86AS PER OUR REPORT OF EVEN DATEFor S S KHANDELWAL & CO., J. Saxena Alok Saxena Yusuf Karim KhanChartered Accountants Managing Director Whole Time Director Executive Director(Firm Registration No:105064W)(S S KHANDELWAL) M. V. Thomas S. P. Date(Proprietor) Chief Financial Offcer Company SecretaryMembership No.31487Mumbai, 18th August, 2009 49
    • CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2009 (Rs. in Lacs) 2008-2009 2007-2008 (A) CASH FLOW FROM OPERATING ACTIVITIES : Net Proft before tax & extraordinary items 6,467.99 5,859.05 Add : Adjustment for - Depreciation 1,649.17 1,124.60 Interest paid 5,078.28 3,739.34 Exchange loss(gain)(net) on loans 475.57 147.14 Dividend Received (3.94) (165.95) Interest Received (173.40) (243.81) Other income (considered separately) (585.76) (404.08) 6,439.92 4,197.24 Operating Proft before working capital changes 12,907.91 10,056.29 Working capital changes - Less: Increase in Sundry Debtors (1,561.77) (3,807.57) Increase in Loans & Advances (1,369.67) (4,098.65) Increase in Inventories (5,445.04) (443.00) (Increase)/Decrease in Other Current Assets (88.07) 159.20 (Decrease)/Increase in Current Liabilities 2,577.95 9,048.31 (including working capital fnance) (5,886.60) 858.29 CASH GENERATED FROM OPERATIONS 7,021.31 10,914.58 Interest paid (5,078.28) (3,739.34) T adjustments ax (1,050.00) (960.00) Cash fow before Extraordinary Items 893.03 6,215.24 Net Cash Flow from Operating Activities - I 893.03 6,215.24 (B) CASH FLOW FROM INVESTING ACTIVITIES : Purchase of Fixed Assets (12,472.53) (10,388.71) Sale of Fixed Assets 59.84 175.69 Purchase of Investments (1,575.00) 5,796.01 Exchange loss/(gain)(net) on loans (475.57) (147.15) Interest Received 173.40 243.81 Dividend Received 3.94 165.95 Other Income Received 585.76 404.08 Net Cash Used in Investing Activities - II (13,700.16) (3,750.32) Cash fow after investing Activities - III = (I-II) (12,807.13) 2,464.9250
    • 14th Annual Report 2008-09CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2009 (Contd...) (Rs. in Lacs) 2008-2009 2007-2008 (C) CASH FLOW FROM FINANCING ACTIVITIES : Share Capital Money received - 6.53 Share Premium Money received - 129.99 Employees Stock Option Scheme - (46.54) Share Application Money Pending Allotment - (136.52) Proceeds from Long Term Borrowings (net of 14,710.50 (2,158.82) repayment) Dividend Paid (471.44) (471.44) T on distributed Dividend ax (80.12) (80.12) Net Cash fow from Financing Activities - IV 14,158.94 (2,756.92) Net Cash fow after Financing Activities 1,351.81 (292.00) Cash and Cash Equivalents Opening Cash and Cash Equivalents 6,379.18 6,671.18 Closing Cash and Cash Equivalents 7,730.99 6,379.18 1,351.81 (292.00)AS PER OUR REPORT OF EVEN DATEFor S S KHANDELWAL & CO., J. Saxena Alok Saxena Yusuf Karim KhanChartered Accountants Managing Director Whole Time Director Executive Director(Firm Registration No:105064W)(S S KHANDELWAL) M. V. Thomas S. P. Date(Proprietor) Chief Financial Offcer Company SecretaryMembership No.31487Mumbai, 18th August, 2010 51